<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405808</url>
  </required_header>
  <id_info>
    <org_study_id>RIMON_R_00961</org_study_id>
    <secondary_id>EUDRACT # : 2006-001711-30</secondary_id>
    <nct_id>NCT00405808</nct_id>
  </id_info>
  <brief_title>Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose</brief_title>
  <acronym>PRADO</acronym>
  <official_title>A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:

      To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting
      Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of
      12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with
      impaired fasting blood glucose and with or without associated comorbidities.

      Main Secondary objectives:

      To determine the effect of 12 months Rimonabant treatment versus placebo on changes in waist
      circumference (WC), body weight, glycemic parameters and lipid parameters.

      To assess the safety of 12 months Rimonabant treatment versus placebo in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    EMEA recommendation to suspend Acomplia marketing authorisation
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the co-primary endpoint : FPG, HDL-C and triglyceride levels.</measure>
    <time_frame>From baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Waist circumference and body weight</measure>
    <time_frame>At each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic parameters (FPG, fasting insulinemia, HbA1c), lipid parameters (Total Cholesterol, HDL-C, LDL-C, triglyceride levels), inflammatory parameter (Hs-CRP),</measure>
    <time_frame>All these laboratory parameters will be measured prior to baseline, month 3, month 6 and month 12.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (IWQOL questionnaire completion)</measure>
    <time_frame>At baseline, month 3, month 6, month 9 and month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events in each group, including neuro-psychiatric adverse events</measure>
    <time_frame>From the signature of the ICF to the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard laboratory assessments</measure>
    <time_frame>Prior to baseline and month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2666</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of one tablet containing 20 mg of Rimonabant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of one Rimonabant placebo tablet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>Once daily in the morning</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily in the morning</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 30Kg/m², or &gt; 27kg/m² if associated with risk factor(s) such as dyslipidemia,
             and &lt; 40kg/m²,

          -  Waist Circumference &gt; 88 cm in women; &gt; 102 cm in men,

          -  Confirmed (by at least 2 measurements) impaired Fasting Plasma Glucose (FPG ≥ 100
             mg/dl (5.6 mmol/L) and &lt; 126 mg/dl (7.0 mmol/L) in non diabetic patients,

          -  LDL cholesterol up to 155 mg/dl (4.00 mmol/L) including patients on a stable dose of
             statin therapy for at least 8 weeks prior to screening,

          -  Current treatment with statins and/or ezetimibe and/or antihypertensive therapy must
             be at fixed and stable dose for at least 8 weeks prior to screening visit,

          -  Patients, who are willing and in the opinion of the Investigator safely assumed to
             remain on stable and fixed doses of antihypertensive, and/or statins and/or ezetimibe
             without adding additional medications or changing current treatment for the duration
             of the trial.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women, or women planning to become pregnant or breastfeed
             (excluded by pregnancy test),

          -  Absence of medically approved contraceptive methods for female of childbearing
             potential,

          -  History of very low-calorie diet within 3 months prior to screening visit (lower than
             1200 Kcal/day),

          -  Weight change &gt; 5 kg within 3 months prior to screening visit,

          -  History of surgical procedures for weight loss (e.g., stomach stapling, bypass),

          -  History of bulimia or anorexia nervosa as per DSM-IV criteria,

          -  Presence of any clinically significant endocrine disease according to the
             investigator, in particular known abnormal TSH and free T4 blood level (Patients
             treated with thyroid replacement therapy must be on fixed and stable dose for at least
             3 months prior to screening and must be in euthyroïd status),

          -  Established type 1 or 2 diabetes treated, or with at least 2 measures of fasting blood
             glucose ≥ 126 mg/dl /L,

          -  Triglyceride level &gt; 400 mg/dL (4.52 mmol),

          -  Systolic blood pressure &gt; 160 mm Hg or diastolic blood pressure &gt;100 mmHg at screening
             visit,

          -  Known severe renal dysfunction (creatinine clearance &lt; 30 ml/min) or nephrotic
             syndrome or urinalysis (performed at screening by dipstick) showing 2+ or more
             protein,

          -  Known severe hepatic impairment or AST and/or ALT &gt; 3 times the upper limit of normal
             at screening,

          -  Presence of any condition (medical, including clinically significant abnormal
             laboratory tests, psychological, social or geographical) actual or anticipated that
             the investigator feels would compromise the patient's safety or limit his/her
             successful participation to the study. In particular :

               -  Cardiac abnormalities: cardiac failure status NYHA III or IV, relevant acute
                  abnormal finding seen on ECG at screening or within 6 months before screening,

               -  Any current malignancy or any cancer within the past five years (except
                  adequately treated basal cell skin cancer or cervix carcinoma in situ),

               -  Significant haematology abnormalities (haemoglobin &lt; 100 g/L and/or neutrophils &lt;
                  1.5 G/L and/or platelets &lt; 100 G/L),

               -  Acute psychiatric disorders or mental condition which could interfere with the
                  patient's compliance or safe participation in the study,

               -  Patient treated for epilepsy,

          -  Ongoing major depressive illness,

          -  Uncontrolled psychiatric illness,

          -  History of alcohol or other substance abuse,

          -  Hypersensitivity /intolerance to the active substance or to any of the excipients such
             as lactose,

          -  Administration of any investigational treatment (drug or device) within 30 days prior
             to screening,

          -  Previous participation in a Rimonabant study or previous administration of Rimonabant,

          -  Administration of any of the following within 3 months prior to screening visit:

               1. Anti obesity drugs (eg, sibutramine, orlistat),

               2. Other drugs for weight reduction (phentermine, amphetamines),

               3. Herbal preparations for weight reduction,

               4. Nicotinic acid, fibrates or bile acid sequestrants ,

               5. Prolonged use (more than one week) of systemic corticosteroids, neuroleptics.

               6. Omega-3 fatty acid approved medication

          -  Ongoing antidepressive treatment(including bupropion)

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Pilorget, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Diegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Horsholm</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Kallithea</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Luxembourg</city>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lysaker</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Luxembourg</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>January 25, 2011</last_update_submitted>
  <last_update_submitted_qc>January 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

